Azenta, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Azenta, Inc. on September 11, 2026, regarding events occurring between August 22, 2026, and September 14, 2026. The filing details the formalization of compensation for the Interim President and Chief Executive Officer and the issuance of retention awards to key executive officers.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and corporate governance changes.
Material Changes
- Interim CEO Compensation: The Board approved a letter agreement with Dr. Martin D. Madaus, effective August 22, 2026. Terms include an annual base salary of $600,000 and a cash performance recognition bonus of $600,000 (100% of base salary). The bonus vests on the first anniversary of the start date or pro rata upon earlier termination, subject to forfeiture for Cause or voluntary resignation.
- CEO Equity Grant: Dr. Madaus was granted restricted stock units (RSUs) with an award value of $1,200,000 on September 14, 2026. These units vest monthly over 12 months.
- Executive Retention Awards: One-time RSU retention awards were approved for four named executive officers with a total aggregate value of $2,500,000:
- Lawrence Lin (CFO): $1,000,000
- Ephraim Starr (General Counsel): $500,000
- Olga Pirogova (CHRO): $500,000
- Trey Martin (President, Multiomics): $500,000
- Committee Restructuring: The Nominating and Governance Committee was reconstituted on September 14, 2026, with William L. Cornog as Chair. Dr. Madaus ceased serving on this committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risks and contingencies relate to the vesting conditions of the compensation packages, which are contingent upon continued employment and subject to the Company's Clawback Policy. The cash bonus for the Interim CEO is also subject to the execution of a general release of claims.
Key Facts for Investor Verification
- Verify the total equity dilution impact of the $3.7 million in new RSU grants ($1.2M to CEO + $2.5M to executives) based on the 20-day average stock price.
- Confirm the specific vesting schedules and forfeiture conditions for the Interim CEO's cash bonus and equity.
- Review the definition of "Cause" and "Good Reason" in the Company's 2020 Equity Incentive Plan to understand termination triggers.
- Monitor the status of the search for a permanent CEO, as Dr. Madaus is currently serving in an interim capacity.